KR20090089815A - Composition for improvement of exercise performance, fatigue recovery and antioxidation activity comprising mixture of panax species plant leaf extract and processed panax species plant leaf extract - Google Patents

Abstract

A composition for enhancing exercise ability, fatigue recovery and antioxidation activity is provided to increase exercise capability and suppress the accumulation. A composition for enhancing exercise ability, fatigue recovery and antioxidation activity comprises leaf extract of Panax sp. plant and its processed material. A method for producing leaf extract of Panax sp. plant and its processed material comprises: a step of reflux-extracting leaves of Panax plant to obtain leaf extract; a step of adding water and acetic acid and stirring at 60-100‹C to obtain processed material of leaf extract; and a step of mixing leaf extract of Panax sp. plant and processed material.

Description

Composition for improvement of exercise performance, fatigue recovery and antioxidation activity containing mixture of Panax species plant leaf extract and processed Panax species plant leaf extract}

This research was carried out by the grant support [Task No. (# PF0321204-00)] of the 21st Century Frontier R & D Program.

The present invention relates to a composition for enhancing athletic performance and fatigue recovery and antioxidant composition containing a mixture of the leaf extract of the genus Panax and the leaf extract processed product of the genus Panax as an active ingredient.

In general, when muscles are not continuously exercised, muscle function decreases with aging and muscle mass and neuromuscular junctions (motor units) decrease, causing fatigue and lethargy. Drop sharply (Dohergy TJ, J Appl. Physiol., 95: 1717-1727, 2003; Eric E, et al., Physiol. Behav., 92 (1-2): 129-135, 2007).

In order to prevent this, it is recommended to continue proper exercise such as resistance training and to have an appropriate diet together. However, most modern people who are chased by busy daily life want to get help from dietary supplements that claim nutrient tonic benefits including ginseng and red ginseng. Regular exercise has become a part of life for modern people to improve their quality of life, and not only athletes but also ordinary people want more energy and endurance in their daily lives. Ginseng root extract of various formulations for feeding is one of the candidates for which many studies have been conducted to verify the efficacy of ginseng in enhancing exercise ability.

Ginseng has long been known as a natural ergogenic aid and has been shown to vary widely in efficacy, ranging from tonic, antioxidant and hangover effects (Kim SH, et al., J Sports Med. Phys). Fitness., 45 (2): 178-82, 2005). Panax ginseng, in particular, has been reported to act on ginsenosides Rg1 and Rb1 to improve mitochondrial energy metabolism and enhance aereobic exercise performance (Wang LC, et al., Planta Med. , 64 (2): 130-133, 1998). In addition, ginsenosides known to be active ingredients of ginseng have been reported to reduce oxidative stress due to antioxidant effects on Rg3 and Re (Tian J, et al., Neurosci. Lett., 374 (2)). : 92-97, 2005; Cho WC, et al., 2006, Eur. J. Pharmacol., 550 (1-3): 173-179, 2006). It has also been reported to reduce the release of plasma creatine kinase (CK) during strenuous exercise, thereby preventing skeletal muscle cell membrane damage (Hsu CC, et al., World J. Gastroenterol., 11). (34): 5327-5331, 2005). Ginseng is believed to have pharmacological effects related to anti-aging, immune enhancement, anti-cancer, anti-stress, antioxidant and long-term protective effects (Gillis CN, Biochem Pharmacol., 54 (1): 1-8, 1997; Attele AS, et. al., Biochem Pharmacol., 58 (11): 1685-93, 1999; Shin HR, et al., Cancer Causes Control., 11 (6): 565-76, 2000).

Ginseng root has been used as an ergogenic aid for endurance exercise and has been consumed by many athletes around the world to promote stamina enhancement and quick recovery from injury. Ginseng roots increase exercise duration until exhaustion, reduce malondialdehyde (MDA) and increase cat (catalase) and superoxide dismutase (SOD). After ginseng root intake [2g, 3 times a day, administered to sedentary humans], CAT and SOD activities, which are scavenger enzymes, were increased and decreased MDA levels (J. Sports Med). Phys Fitness. 2005, 45 (2): 178-82).

Panax Notogenes has also been reported to increase exercise duration before exhaustion (J Strength Cond Res., 2005 19 (1): 108-14). Ginseng roots have been reported to improve lung function and exercise ability in patients with Chronic Obstructive Pulmonary Disease (COPD) (Monaldi Arch Chest Dis. 2002, 57 (5-6): 242-6). Red ginseng roots increase the time it takes to run out of treadmill exercise and prevent the exercise-induced serotonin synthesis and increased expression of tryptophan hydroxylase. This suggests that red ginseng root intake can function as an ergogenic mechanism by exhibiting the effect of inhibiting serotonin levels during exercise (J. Pharmacol Sci. 2003, 93 (2): 218-21).

Panax ginseng leaves are known to have antioxidant and hypoglycemic activity, which can prevent the rapid increase in blood glucose levels and, as a result, reduce TBARS levels in diabetic rats (J Ethnopharmacol. 2005 98 (3): 245). -50). American ginseng leaves have been reported to have anti-hyperglycemic and thermogenic activities (Pharmacol Res., 2004, 49 (2): 113-7).

However, there is little clinical evidence demonstrating improved body endurance by taking ginseng products (J Am Coll Nutr. 1998, 17 (5); 462-6, Int J Sport Nutr. 1996 6 (3): 263-71; J Am Diet Assoc 1997, 97: 1110-5 and J Strength Cond Res., 2001, 15 (3): 290-5), if present, were experiments with professional athletes (Forgo I, MMW Munch Med Wochenschr., 125 (38): 822-4, 1983) and experiments with sports teachers (Pieralisi G, et al., Clin Ther., 13 (3): 373-82 , 1991). However, ginseng roots have been reported to have no effect on the maximum oxygen uptake (VO ₂ max) and lactate threshold (LDH) of football players (Int J Sport Nutr. 1999 9 (4): 371-7), physically active It has been reported that the Thai did not alter lactate threshold and exercise performance (J Med Assoc Thai 2007 90 (6): 1172-9), which indicates aerobic fitness of well-fit people with well-fitted ginseng roots. It does not show an ergogenic effect on augmentation.

Ginseng roots have not been reported to promote anabolic hormonal status following persistence exercise (J Strength Cond Res., 2002 16 (2): 179-83), and Illuterococcus (Gaciosapi) , Eleutherococcus, has not been reported to support ergogenic effects on metabolic, behavioral, or psychological parameters associated with submaximal and maximal aerobic exercise tasks (Med Sci Sports Exerc. 1996, 28 (4): 482-9). ). In addition, research results have been reported that ginseng root extract may increase aerobic exercise performance when a large number of subjects ingested more than 2 g of standardized ginseng extract per day to obtain the effect of exercise in ginseng. Am J Clin Nutr., 2000, 72: 624S-36S.

As such, there are no specific research results to prove the efficacy of ginseng related to the improvement of athletic ability of not only athletes but also the general public.

Ginsenoside is a special group of triterpenoid saponins and can be classified into two groups, dammarane type and oleanane type, depending on the structure of aglycone. Ginsenosides are found specifically in the genus Panax, with more than 150 naturally occurring ginsenosides isolated from the roots, leaves / stems, fruits or flower heads. Ginsenosides have been the subject of numerous studies because they are considered to be the main active substance that shows the efficacy of ginseng. Ginsenoside is an important physiologically active component of ginseng, and the sugar chain of ginsenoside is closely related to physiological activity. Ginseng saponins (ginsenosides) are extracted from the roots and leaves of ginseng. Many studies have been focused on converting major ginsenosides to Rg3, a more active minor ginsenoside. Due to the difficulty in preparing ginsenosides Rg3 and Rg2, compounds have been prepared by heating, enzymes and strong acid treatment (Phytochemistry 2004, 65 (3): 337-44, Phytochemistry 2008, 69 (1): 218-24, Chem Pharm Bull 2003 51 (4): 404-8).

On the other hand, supplements containing compounds such as steroids, caffeine, sodium bicarbonate and sodium citrate can significantly increase exercise performance when taken in a certain amount, but such drugs may have fatal side effects and ultimately harm health. There is this.

Therefore, recently, studies to develop functional supplements using safe natural products such as plant extracts have been actively conducted. For example, Korean Patent Registration No. 526164 discloses a composition for enhancing exercise performance including squalene and plant extracts. This is described.

The present invention has been made in accordance with the above requirements, the inventors of the present invention, while effectively studying the adjuvant without side effects, which effectively enhance exercise performance and fatigue recovery, and have antioxidant efficacy, leaf extract and panax of Panax genus plants The present invention was completed by confirming that the exercise performance was increased and the accumulation of fatigue components in the blood was suppressed when the composition containing the mixture of the leaf extract processed material of the genus plant was ingested.

In order to solve the above problems, the present invention provides a composition for enhancing athletic performance and fatigue recovery and antioxidant composition containing a mixture of the leaf extract of the genus Panax plant and the leaf extract of Panax genus plants as an active ingredient.

Preferably, the total ginsenoside content in the leaf extract of the genus Panax and the processed product of the leaf extract is 30 wt% or more, preferably 40 wt% or more, and contains 90% or more saponins.

Preferably, the present invention comprises a leaf extract of the genus Panax plant and a mixture of the processed product of the leaf extract comprises a 3-O-glycoside derivative of Protopanaxanatriol and a 3-O-glycoside derivative of Protopanaxadiol To provide a composition.

According to one embodiment of the present invention, the leaf extract of the genus Panax plants and the mixture of the processed extracts of the leaf extract are used for improving athletic performance and fatigue, containing one or more components selected from the group consisting of ginsenosides Rg3, Rg5 and Rk1. Promoting or antioxidant compositions are provided.

In the mixture of the leaf extract of the genus Panax plants according to the invention and the processed product of the leaf extract, the total content of Rg3, Rg5 and Rk1 components in the extract is preferably 5 wt% or more, more preferably 10 wt% or more.

In the composition according to the present invention, the leaf extract powder of the genus Panax and the leaf extract powder processed product may be mixed in a ratio of 1: 0.1 to 10, preferably 1: 0.1 to 5, more preferably 1: 0.1 to 3, even more preferably 1: 0.5 to 2.

In the present invention, the Panax genus plants are Panax ginseng , Panax japonicum , Panax quinquefolium , Panax notoginseng , Panax trifolium and Panax Pseudomonas ginseng (Panax pseudoginseng), Vietnamese ginseng (Panax vietnamensis), may be selected from the group consisting of Panax elegans are tees climb (Panax elegatior), Panax Wan Jia Taunus (Panax wangianus) and Panax non pinra typhimurium Douce (Panax bipinratifidus) .

The leaf extract of the genus Panax plants of the present invention and the mixture of the processed extract of the leaf extract include squalene, triticale water extract, agapi water extract, Cordyceps sinensis extract, cola nut powder or extract, vitamins, minerals, taurine, phosphatidylcholine, glutamine, L It may further comprise one or more components selected from the group consisting of arginine and L-carnitine.

The composition according to the present invention enhances the exercise performance time when ingested, and has the effect of inhibiting the accumulation of blood fatigue substances and antioxidant effects, as well as the aerobic exercise ability, that is, cardiopulmonary exercise endurance according to the maximum oxygen intake. It is useful for improving physical strength and athleticism and is safe for human consumption.

In order to achieve the object of the present invention, the present invention provides a composition for enhancing athletic performance and fatigue recovery and antioxidant composition containing a leaf extract of Panax genus plants and a mixture of the leaf extract processed product as an active ingredient.

In the composition according to the embodiment of the present invention, the total ginsenoside content in the leaf extract of the genus Panax is 30 wt% or more, preferably 40 wt% or more, and contains 90% or more saponins. When the ginsenoside total content ratio is more than the above-mentioned range, excellent effects can be obtained in terms of enhancing athletic performance, promoting fatigue recovery, and antioxidant efficacy.

According to a preferred embodiment of the present invention, the leaf extract of the genus Panax plant and the mixture of the processed product of the leaf extract are a 3-O-glycoside derivative of protopanaxanatriol and a 3-O-glycoside derivative of protopanaxadiol A composition comprising: a 3-O-glycosidic derivative of ProtoPanaxatriol versus a 3-O-glycosidic derivative of ProtoPanaxadiol in a mixture of leaf extracts of Panax plants and processed products of the leaf extracts; The content ratio is 1: 0.1 to 1.5, more preferably 1: 0.5 to 1.5, and even more preferably 1: 0.7 to 1.5. Here, the 3-O-glycoside derivatives of the protoparnaxatriol include Re, Rg1 and Rg2, and the 3-O-glycoside derivatives of the protoparnaxadiol include Rb1, Rb2, Rb3, Rc, and Rd. , Rg3 (R, S), Rg5, Rk1 and the like. When the content ratio of the triol to diol is within the above range, it is possible to obtain an excellent effect in terms of exercise performance, fatigue recovery promotion, antioxidant efficacy.

In the composition according to the embodiment of the present invention, the leaf extract of the genus Panax and the mixture of the processed product of the leaf extract contain one or more components selected from the group consisting of ginsenosides Rg3, Rg5 and Rk1.

In the composition according to the embodiment of the present invention, the leaf extract of the genus Panax and the mixture of the processed extract of the leaf extract may contain protopanaxadiols such as Rg3, Rg5 and Rk1 in an amount of 5% or more of the total extract weight. Contains in proportions. In addition, the mixture of both the leaf extract of the genus Panax and the processed product of the leaf extract contains at least 10% of the total extract weight of protopanaxadiols such as Rg3, Rg5 and Rk1. When the total content ratio of the Rg3, Rg5 and Rk1 is within the above range, it is possible to obtain an excellent effect in terms of exercise performance, fatigue recovery promotion, antioxidant efficacy.

Table 1 shows the results of comparing the ginsenoside content of the leaf extract of the genus Panax plant and the processed product of the leaf extract (UG0712) with commercial ginseng products, and the leaf extract of the genus Panax plant of the present invention is commercially available. It can be seen that the ginsenosides content is significantly higher than other ginseng products.

Table 1.Comparison Table of Ginsenoside Contents of UG0712 and Commercial Ginseng Products

product Company Name result Rg3, Rg5, Rk1 Total Ginsenoside UG0712 (mixture of UG0407 and UG0507) Unigen 10.01% 41.05% UG0714 (Ginseng Root Extract) Commodity 0.79% 8.04% Ginseng Gold, Korean Ginseng Root GNC 0.34% 4.97% Ginseng Gold, Standardized American Ginseng GNC 0.17% 4.10% American Ginseng Extract Johnson & Barana 0.35% 11.48% Pharmaton BoehringerIngelheim N.D 1.7% Nature's Resource® Ginseng Nature's resource 0.17% 11.24% GinSynergy BIOGLAN 0.09% 6.09% Ginseng Panax Integratore alimentare BODY SPRING 1.04% 6.02% American Ginseng PE STAUBER 0.41% 10.50% Panax Ginseng PE STAUBER 0.1% 3.4% American ginseng powder Hsu's ginseng 0.35% 8.01% American Ginseng Root PE 1% ginsenosides Q NATUREX 0.1% 2.1% Ginsenipure Ginseng americ NATUREX 0.43% 18.43%

Protopanaxadiols such as Rg3, Rg5 and Rk1 contained in the mixture of both the leaf extract of the genus Panax plant according to the present invention and the processed product of the leaf extract thereof have the structure and physicochemical properties as shown in Table 2 below. Has characteristics.

Table 2. Structural and Physicochemical Characteristics of Rg3, Rg5 and Rk1

Ginsenosides name 20 (S, R) -Rg3 Rg5 Rk1 Ginsenoside structure

20S-Rg3 ->R1 = OH 20R-Rg3 ->R2 = OH

20S-Rg3-> R1 = OH 20R-Rg3-> R2 = OH

Molecular formula C ₄₂ H ₇₂ O ₁₃ C ₄₂ H ₇₂ O ₁₃ C ₄₂ H ₇₀ O ₁₂ C ₄₃ H ₇₄ O ₁₂ Molecular Weight 785.023 785.0343 767.0078 783.0504 Constellation White powder White powder White powder White powder Melting Point (℃) 248 ~ 250 ℃ 299 ~ 303 ℃ 186 ~ 188 ℃ 178 ~ 181 ℃ Solvent Alcohol DMSO Alcohol Alcohol

The Panax genus plant is Panax ginseng (Panax ginseng), Panax chair pony glutamicum (Panax japonicum), Panax kwinkeu poly Titanium (Panax quinquefolium), Panax Noto Ginseng (Panax notoginseng), three yeopsam (Panax trifolium) and Panax pseudo Ginseng (Panax pseudoginseng), Vietnam, three (Panax vietnamensis), but the like Panax elegans tee climb (Panax elegatior), Panax Wan Jia Augustine (Panax wangianus) and Panax non pinra Tippi Douce (Panax bipinratifidus), but is not limited thereto.

In the composition according to an embodiment of the present invention, the leaf extract of the genus Panax plant and the mixture thereof may be in powder form, but is not limited thereto. The powder form of the extract may be prepared using a method such as freeze drying, hot air drying, drying by electromagnetic waves of the leaf extract of the genus Panax plant.

In the composition according to the embodiment of the present invention, the leaf extract powder of the Panax genus plant and the leaf extract powder of Panax genus plant may be mixed in a ratio of 1: 0.1 to 10, preferably 1: 0.1 to 5 More preferably from 1: 0.1 to 3, more preferably from 1: 0.5 to 2.

In the composition according to the embodiment of the present invention, the mixture of the extract of the leaf extract powder of the genus Panax and the leaf extract powder of the genus Panax plant is the following steps, that is,

(a) extracting reflux by adding an extraction solvent to the leaves of the genus Panax plant, and then lyophilizing to obtain a leaf extract powder of the genus Panax plant;

(b) adding water and glacial acetic acid to the obtained extract powder, performing a processing reaction with stirring at 60-100 ° C., and drying to obtain a processed product of the leaf extract powder of the genus Panax plant; And

(c) mixing the processed material of the leaf extract powder of the genus Panax plant obtained in step (a) and the leaf extract powder of the genus panax plant obtained in step (b):

It can be obtained via.

The extraction solvent may be water, a C _1-4 alcohol, or a mixed solvent thereof, and the alcohol is preferably ethanol, more preferably 70% ethanol.

The composition of the present invention may further contain at least one active ingredient exhibiting the same or similar function in a mixture of the leaf extract of the genus Panax plant and the leaf extract of Panax genus plant.

The composition according to one embodiment of the present invention is squalene, triticale water extract, Ogai water extract, Cordyceps sinensis extract, collagen powder or extract, vitamins, minerals, taurine, creatine, phosphatidylcholine, glutamine, L-arginine and L-carnitine It may further comprise one or more components selected from the group consisting of.

The water extracts of the three hundred s, Ogapi and Cordyceps sinensis can be prepared and used according to known methods, or the water extracts can be purchased and used commercially.

Squalene is a polyunsaturated hydrocarbon with six double bonds, usually prepared by extracting and refining it in the liver oil of a deep sea shark. The physiological activities of squalene include oxygen supply and sterilization. In particular, squalene is known to bind oxygen and release oxygen from the water molecules of the human body, thereby activating the cells by releasing oxygen to supply the cells in the body.

Three hundred seconds is an old grass and its pharmacological action is very diverse. That is, it is known to have a remarkable effect on the prevention and treatment of adult diseases such as constipation, diabetes, liver disease, cancer, hypertension, heart disease, gynecological diseases and kidney disease.

Ogapi refers to dried roots and bark of the bark of the arthropod and deciduous shrub, and is known to be prescribed for stomach, arthritis, back pain, degenerative arthritis syndrome, species, each, bruises and swelling.

Cordyceps sinensis is a small mushroom belonging to the Aspergillus fungi, and most of them are parasitic to insects and give fruit bodies to the host of insect host. Cordyceps sinensis is known to have a physiological activity that purifies the bronchus, removes impurities attached to blood vessels, and strengthens the contractile force of the heart. It is also known to be effective in activating and restoring cells, strengthening immunity, normalizing blood glucose levels, anemia and obesity.

The amino acids such as taurine, creatine, glutamine, L-arginine, and L-carnitine may be used as direct energy sources to help muscle fatigue after exercise.

Phosphatidylcholine is a compound of fat, phosphorus and nitrogen, present in large amounts in egg yolk, soybean oil, liver, brain and the like. It is one of the important components of cell membrane composition and is known for fatigue recovery.

Colanut is a fruit belonging to the Sterculiaceae family and contains the caffeine of Cola acuminata and C. nitida. Native to tropical Africa, it is used as a raw material for non-alcoholic beverages and medicines and as a herbal medicine to treat drug addiction, hangover and diarrhea. The collagen contained in the composition of the present invention may be in the form of an extract or powder form.

Vitamins used in the present invention include vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , nicotinic acid amide, vitamin C, and minerals include MgCl ₂ , KCl, NaCl, Ca-lactate, ammonium citrate, etc. These can be used in combination.

The composition of the present invention can be used as a composition for enhancing exercise ability and fatigue recovery and a composition for inhibiting oxidation reaction.

In addition to the above-described active ingredient for the administration of the composition may be prepared containing one or more pharmaceutically acceptable carriers. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

The compositions of the present invention may be administered parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) or orally, depending on the desired method, and the dosage may be based on the weight, age, sex, health status, The range varies depending on the diet, the time of administration, the method of administration, the rate of excretion and the severity of the disease.

In the composition according to an embodiment of the present invention, the leaf extract of the genus Panax plant and the mixture of the processed extract of the leaf extract has the ability to enhance the exercise ability, inhibit the accumulation of fatigue substances and antioxidant effect, aerobic exercise according to the maximum oxygen intake The ability to improve cardiopulmonary endurance is effective in improving physical strength and athletic ability.

In more detail, the leaf extract of the genus Panax plant according to the present invention and the mixture of the processed product of the leaf extract improve the animal's motility, CK (creatine kinase), LDH (lactate dehydrogenase), lactate, corticosterone inhibits muscle and / or blood accumulation due to fatigue factors such as (corticosterone), improves exercise performance by increasing type I muscle or citricate synthase (CS) activity associated with improved motor performance, and NO (nitric oxide) inhibition, SOD (syperoxide dismutase) oxidation inhibition rate, GPx (glutathione peroxidase) inhibits the oxidative reaction by increasing the activity, VO ₂ max increase, AT (Anaerobic Threshold) increase the ability to exercise Can be improved.

Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are merely to illustrate the invention, but the content of the present invention is not limited to the following examples.

Example

Experimental Example 1. Preliminary Process

(1) Obtaining, quarantining, and purifying experimental animals

Seven week-old SD rats were obtained and subjected to veterinary quarantine on the general health of all animals. Approximately 7 days of acclimatization were required to select healthy animals suitable for conducting the test, and experimental animals were bred at a temperature of 22 ± 2 ° C, a humidity of 50 ± 20%, and 12hr / day / night.

(2) Selection of experimental animals and separation of groups

 In order to select a healthy individual with a certain ability to exercise, a treadmill exercise is performed on animals that have undergone a period of purification prior to group separation to remove outliers, and then based on weight. Groups were separated by random group placement.

(3) individual identification

The box was affixed with an identification card containing the test number, sex, group number, individual number, dose, duration of testing, and name of the investigator. Individual identification was performed using tail marking using oily magic.

(4) Preparation of test substance

1) Preparation of Ginseng Root Concentrate Powder

1 kg of Panax ginseng root was added to 10 L of 70% ethanol and refluxed three times for 7 hours. The primary, secondary and tertiary extracts were mixed and filtered using a 5 μm filter housing. The filtrate (28L) was concentrated using a vacuum concentrator to 20 Brix%. 1 kg each of the concentrate in the freeze-dried tray was frozen for 48 hours in a freeze dryer (deep freezer) of -70 ℃. The freeze-concentrated concentrate was placed in a freeze dryer and lyophilized for 48 hours to obtain 542 g (yield: 54.2%) of ginseng concentrate powder.

2) Preparation of Ginseng Leaf Extract Powder

2.5 kg of Panax ginseng leaf was added to 25L of 70% ethanol and refluxed for 5 hours. The extract was filtered using a 5 μm filter housing. The filtrate (22L) was concentrated using a reduced pressure concentrator to 15Brix%. The concentrated solution was placed in a freeze-drying tray for 1 kg and frozen for 48 hours in a -70 ° C deep freezer. The freeze-finished concentrate was placed in a freeze dryer (Ilsin Lab, Korea) and lyophilized for 48 hours to obtain 354 g of ginseng leaf extract powder (yield: 14.16%).

3) Preparation of Ginseng Leaf Extract Powder

The ginseng leaf extract powder (100 g) prepared by the method 2) is placed in a round bottom flask (2L). And purified water 360 ~ 380mL and 20 to 40 ml (5 ~ 10%) glacial acetic acid was added. The mixture was heated with stirring at 60-100 ° C. for 2-6 hours. Extract (400 ml) was concentrated to 20 Brix% using a vacuum concentrator. The concentrates were placed in a lyophilization tray and frozen for 48 hours in a -70 ° C deep freezer. The freeze-concentrated concentrate was placed in a freeze dryer and lyophilized for 48 hours to obtain 92.5 g (92.5%) of ginseng leaf extract.

4) Preparation of Mixture of Ginseng Leaf Extract and Ginseng Leaf Extract Processing

350 g of ginseng leaf extract prepared by Method 2) and 650 g of the ginseng leaf extract processed product prepared by Method 3) were mixed for 20 minutes using a ribbon mixer to obtain a mixture of 990 g (yield: 99%).

Dose of each test substance is shown in Table 3 below, 0.5% Tween 20 (negative control), ginseng root concentrate powder and ginseng leaf extract and ginseng obtained in 1), 4) The mixture of leaf extract processed products was dissolved in 0.5% Tween 20 using an ultrasonic mill to prepare a positive control group and a test group, respectively.

Table 3. Test Substances

group Dosage (mg / kg) Negative control - Positive control group (UG0714) 25 Test group (UG0712) 25

(5) Content Analysis

HPLC used for the analysis for the above production methods 1) -4) was HITACHI (pump; L-7100, detector; L-7455, interface; D-7000, column oven; L-7300, automatic sampler; L- 7200) system, the analysis conditions were Capcell PAK C18 (5㎛), 3.0 * 75mm as stationary phase, mobile phase conditions were gradient conditions with solvent A (acetonitrile), solvent B (water), flow rate 0.5mL The total analysis time at / min was 110 minutes, the temperature of the column oven was set to 40 ° C, the injection amount of the sample was 10 µl, and detected at 203 nm with a UV detector. Ginsenosides Rb1, Rb2, Rb3, Rc, Rd, Re, Rg1 were separated within 60 minutes, and Rg2, Rg3, Rg5, Rk1 were separated after 70 minutes. As a sample for analyzing the processed ginseng lyophilisate prepared according to the method of the present invention was prepared with methanol. Ginsenoside standard samples were prepared at a concentration of 0.2 mg / ml. The analysis results are shown in Table 4 below.

Table 4. Ginsenoside Content Analysis Results

Rb1 Rb2 Rb3 Rc Rd Re Rg1 Rg2 Rg3 (R, S) Rg5 Rk1 UG0714 1.25 0.65 0.17 1.35 1.08 1.82 0.93 ND 0.34 0.36 0.09 UG0712 0.8 1.6 0.5 1.1 7.8 5.7 2.1 12.1 6 2.4 1.8

(6) administration

From the day after the group separation, the exercise group was orally administered to the stomach for 8 weeks and the non-athletic group once daily, using Zonde (zonde).

(7) non-athletic and athletic groups

Negative control group (solvent, 0.5% Tween 20), positive control group (UG0714) and test group (UG0712, mixture of ginseng leaf extract and ginseng leaf extract processed product) resulted in the effect of improving exercise performance and improved fatigue after exercise In order to evaluate the effects and antioxidant effects, rats were orally administered to each test substance for 8 weeks, and the maximum driving distance was measured at 2 and 8 weeks after the start of the administration while increasing the adaptability to exercise on the treadmill. On the other hand, the non-exercise group analyzed the effects of exercise performance after adaptive movement for 5 days before oral measurement for 6 weeks and 9 weeks with oral administration for 9 weeks.

(8) general symptoms observation and weight measurement

General symptoms were observed once daily during the administration period of the test substance and confirmed the occurrence of mortality once daily during the observation period. Body weights of the test animals used for the test were measured immediately before administration of the test substance, once a week after the start of administration of the test substance, and immediately before necropsy upon separation of the reserve group.

(9) Blood and Analytical Sampling at Necropsy

At necropsy, the abdominal cavity was opened and the whole blood was collected through the abdominal vein, and then analyzed in less than 4 hours in an individual container for antipyromarker analysis, blood lactate, and corticosteroid analysis. Muscle samples were buffered with isopentane and frozen with liquid nitrogen to minimize muscle damage. Frozen muscle samples were stored in a deep freezer.

Example 1: The effect of improving the exercise capacity of the mixture of ginseng leaf extract and ginseng leaf extract processed

(1) Experimental process

1) Administration of test substance

The energy boosting effect of the test substance was evaluated by measuring the exercise effect through a treadmill, and the rats were tested, namely, the negative control (0.5% Tween 20 solvent), UG0714 (ginseng root extract, positive control) and UG0712 ( Ginseng leaf extract powder and mixture of ginseng leaf extract processed product, test group) were orally administered.

2) How to measure

A. General Symptom Observation: The general symptoms were observed once a day during the administration period of the test substance, and confirmed the death of once a day during the observation period.

B. Weight measurement: The body weight of the test animals used for the test was weighed once a week after the start of administration of the test substance, immediately before administration of the test substance, upon separation of the preliminary group.

C. Non-Exercise Training and Maximum Momentum Measurements: Ten animals in the non-athletic group were given the test substance for 9 weeks and the maximum exercise was measured at 6 and 9 weeks. In the measurement of the maximum exercise, the maximum running time was measured on the fifth day of training with increasing inclination (0% ~ 15%), speed (20 ~ 40cm / sec) and activity cycle (10 ~ 20 minutes) for 4 days. The lower 2 of 10 measured individuals were removed and the top 8 results were used.

D. Exercise Training and Maximum Momentum Measurements: Nine animals in the exercise group were exercised on the treadmill. Exercise for 4 weeks is slope (0% to 15%), speed (20 to 30 cm / sec) and activity cycle (30 to 40 minutes), for the remaining 4 weeks, 15% slope and speed (30 to 40 cm / sec) Increasing the activity cycle (30-40 minutes) was performed. Animals continued to exercise on a two day cycle with two days of exercise and two days off. At the 2nd and 8th week of the training period, the maximum running time was measured in the exercise group, the lower 2 of 9 measured individuals were removed, and the top 7 measurements were used for the results.

(2) results

As a result of measuring the maximum mileage of rats after 2 weeks of exercise group according to 5% slope, 30 cm / sec, and 90 minutes of electric stimulation induction, a mixture of ginseng leaf extract and ginseng leaf extract processing (UG0712) was administered as shown in FIG. The motor capacity of one rat was significantly increased than that of the negative control group (p <0.00001). In addition, the exercise capacity of UG0712 was significantly increased (p <0.05) than that of rats administered the ginseng root concentrate powder (UG0714).

As a result of measuring the maximum mileage of rats after 8 weeks of exercise according to 15% inclination, 35 cm / sec and 90 minutes of electric stimulation induction, the mixture of ginseng leaf extract and ginseng leaf extract processed product (UG0712) was administered as shown in FIG. Rat exercise capacity increased significantly than that of the negative control (p <0.01). In addition, exercise ability was significantly increased when UG0712 was administered (p <0.005) than rats receiving ginseng root concentrate powder (UG0714).

As a result of measuring the maximum mileage of rats after 6 weeks of non-exercise group according to 5% inclination, 35 cm / sec and 90 minutes of electrical stimulation induction, the mixture of ginseng leaf extract and ginseng leaf extract processed product (UG0712) was administered Rat exercise capacity increased significantly than that of the negative control group (p <0.05). In addition, exercise ability was significantly increased (p <0.05) in rats treated with Ginseng Muscle Concentrate Powder (UG0714) when UG0712 was administered.

As a result of measuring the maximum mileage of rats after 9 weeks of non-exercise group according to 10% inclination, 35 cm / sec and 90 minutes of electric stimulation induction, the mixture of ginseng leaf extract and ginseng leaf extract processed product (UG0712) was administered as shown in FIG. Rat exercise capacity increased significantly than that of the negative control group (p <0.001). In addition, exercise ability was significantly increased (p <0.05) in rats treated with Ginseng Muscle Concentrate Powder (UG0714) when UG0712 was administered.

Therefore, it can be seen that the mixture of the ginseng leaf extract and the ginseng leaf extract processed product of the present invention efficiently enhances the exercise ability of the animal, and the effect is superior to the ginseng root extract or the negative control group.

Example 2. Antipyromarker Measurement

In order to detect the anti-stress effect of test substance on exercise stress by long-term exercise and exhaustive maximum mileage measurement, blood anti-fatigue markers were measured before and after maximal exercise distance in both non-exercise and exercise group. For this purpose, blood was collected by jugular vein collection of blood 1 day before and 20 minutes after exercise to separate serum. Creatine kinase (CK) and lactate dehydrogenase (LDH) were measured using a blood biochemical analyzer (Hitachi 7080, Japan). LDH associated with anaerobic oxidation capacity was measured by absorbance at 37 ℃ spectrophotometer (spectrophotometer), all measurements were expressed in Umol / min / g.

Lactic acid and corticosteroids (AssayMax Corticosterone ELISA Kit, Gentaur, catalog No. EC3001-1) were analyzed in blood obtained after 8 weeks of maximum mileage measurement for the exercise group and after 9 weeks of maximum mileage for the non-athlete group. . The measurement results are as shown in Tables 5 to 12 below.

Table 5. creatine kinase (CK) in exercise group

CK (creatine kinase) is an enzyme that is expressed in various tissues and is involved in the conversion of creatine to creatine phosphate and ADP by consuming ATP. Clinically, blood CK is a myocardial infarction, rhabdomyolysis, severe It can be used as a marker for muscle breakdown, muscular dystrophy and acute renal failure. Damaged muscles increase blood CK levels.

Experimental results show that when UG0712 was administered, CK levels were significantly reduced (FIG. 5), thereby effectively inhibiting muscle damage due to exercise during UG0712 administration.

Table 6. LDH in the non-athletic group

Table 7. LDH in the exercise group blood (after 8 weeks of exercise)

Table 8. LDH in Exercise Muscle

LDH is an enzyme present in the cytoplasm that is reflected in the catalysis between the glycolytic enzyme pyruvate and lactate.In general, post-exercise fatigue causes oxygen to enter muscle cells as a result of long-term intense contractions. Inadequate supply of energy for muscle activity occurs through the anaerobic energy system pathway, resulting in the accumulation of many lactic acid in the muscle, which is a good marker of glycolysis.

When UG0712 was administered to the non-exercise group, blood LDH activity was significantly decreased compared to the negative control group and the positive control group (FIG. 6), and when administered to the exercise group, LDH in the blood and muscle group compared to the negative control group and the positive control group. The concentration of was significantly reduced (FIGS. 7 and 8).

Experimental results showed that the LDH tended to increase as a whole compared to the non-exercise group. This may be due to the increase in LDH enzyme activity due to the increase in muscle load caused by regular exercise.

The LDH activity of the exercise group was significantly decreased when UG0712 was administered, which may inhibit the lactic acid production in the muscle and reduce the fatigue level of the UG0712, which may help to improve the athletic performance in the treadmill.

Table 9. Blood Lactic Acid in Non-Athletic Groups

Table 10. Athletic group lactic acid

Lactic acid, known as one of the main fatigue factors closely related to exercise intensity and duration, is an end metabolism of anaerobic glycolysis, which is produced by the reduction of pyruvate, which increases blood levels due to strong exercise stress. Accumulation can lead to acidification in the body, which in turn inhibits factors related to various glucose angiogenesis.

In the experimental results, when UG0712 was administered to the non-exercise group and the exercise group, blood lactate was significantly reduced compared to the negative control group (Figs. 9 and 10). Thus, when UG0712 was administered, the fatigue factor generated during exercise was reduced. It can be seen that it can improve athletic performance.

Table 11. Serum corticosteroids in non-motor groups

Table 12. Athletic Blood Corticosteroids

Corticosteroids, known as representative stressors, play an important role in glycolysis during exercise, and blood levels vary with intensity. It shows an increase in both endurance and high intensity exercise, and unlike catecholamine, it does not decrease immediately after exercise and maintains the level for a certain period of time. Maintaining high levels of corticosteroids over long periods of time can degrade or damage proteins in the body and cause side effects that can impair nitrogen balance. In the experimental results, the administration of UG0712 in the non-exercise group and the exercise group significantly decreased blood corticosteroids as compared to the negative control group (FIGS. 11 and 12). Therefore, it can be seen that the exercise ability can be further improved by lowering the concentration of the stress factor through the administration of UG0712.

Example 3. Measurement of the effect of improving athletic performance

In general, with respect to exercise, muscle metabolism changes to increase the oxidative power and delay the state of muscle fatigue, and this change is reflected in the activity of mito-oxidative enzymes in the muscle, depending on the duration and intensity of exercise. Change appears. Such mito-oxidizing enzymes include citrate synthase, cytochrome C oxidase, and succinate dehydrogenase, and especially citrate synthase has aerobic oxidative activity. Well known as a good marker. Among the non-exercises and exercise groups, muscles were taken to search for biochemical markers related to motor performance, and the activity of CS (citrate synthase) related to aerobic oxidation was measured.

Muscles were placed in 2 mM MgCl ₂ and 2 mM EDTA solution in 50 mL TRIS and homogenized at 4 ° C. The citrate synthase (CS) related to energy generation by aerobic oxidation in muscle was measured by spectrophotometer at 37 ° C. All measurements were expressed in Umol / min / g.

Table 13. CS activity in muscles of non-exercises (citrate synthase activity)

Table 14. CS activity in muscle of exercise group (citrate synthase activity)

As a result of CS activity analysis, administration of UG0712 to the non-exercise group and the exercise group showed that CS activity was significantly increased (FIGS. 13 and 14). As such, the CS activity associated with energy generation by aerobic oxidation during UG0712 administration increases the maximum consumption of oxygen in the exercise performance and helps the exercise performance, so that the maximum running distance in the treadmill is the test group. It seems to be higher than the exercise control group or the positive control group.

Example 4. Antioxidant Effect Measurement

Oxygen free radicals and reactive oxygen species (ROS) are produced not only in human metabolism but also during intense exercise, which alters proteins and DNA and damages the biofilm, which in turn adversely affects the tissue itself. It has also been reported to cause cancer and adult disease. Enzymes such as mitochondria, peroxysomes, xanthine oxidase, NADPH oxidase and cyclooxygenase (COX) present in cells produce several free radicals (ROS), which cause oxidative damage, In addition, active nitrogen species are produced in a large amount in the inflammatory response, and active oxygen species are also produced together. Inflammatory factors such as NO are produced when intramuscular inflammatory reactions occur due to prolonged and excessive exercise.

The antioxidant system for the removal of excessive free radicals is primarily composed of antioxidant enzymes such as SOD and GPx (glutathione peroxidase) and endogenous non-enzymatic antioxidants such as antioxidant vitamins and glutathione. There is a DNA repair enzyme that restores the components.

To evaluate the antioxidant effect, NO analysis was performed in blood and muscle and SOD and GPx enzyme activity in hind limb muscle.

Inhibition of muscle superoxide dismutase (SOD) was measured using a commercially available SOD kit (superoxide dismutase Assays Designs, Catalog No. 30-023).

Intramuscular GPx (glutathione peroxidase) activity was analyzed using Glutathione Peroxidase Activity Kit (Assays Designs Cat.No. 900-158), which measures GPx by measuring the change (decrease) of NADPH. The formula was used.

Table 15. Blood NO in non-motor groups

Table 16. NO in the muscles of the non-motor group

Table 17. NO in exercise group blood (2 weeks ago)

Athletic group NO in blood (micromole / mL) mean SD Negative Control 144.28 19.46 UG0714 126.00 36.59 UG0712 100.50 27.67

Table 18. NO in exercise group blood (bleeding after 2 weeks)

Table 19. NO in exercise group muscles

Nitric oxide (NO) is synthesized from arginine by the catalysis of nitric oxide synthase (NOS), skeletal muscle blood flow is inhibited by NOS inhibitors, and skeletal muscle blood flow during exercise increases NO. It is known to imply. Therefore, the amount of NO in blood and muscle can be predicted as an indirect indicator of various oxidative stress factors in muscle.

The results of NO analysis in the exercise group 8 weeks after the administration of the test substance showed a lower tendency in the blood than in the non-exercise group compared to the exercise control group. In the UG0712 group, the non-motor test group showed a significant decrease of 62 ± 15.36 micromol / mL compared to the exercise control group. The results of the muscles showed the same value as the blood result in the exercise group, which was higher than the non exercise group, and showed a significant difference. In the non-exercise group, the non-exercise UG0712 group showed a significant decrease of 5 ± 0.44 micromol / mL with the non-exercise control group (p <0.05) and the exercise control group (p <0.01) (FIGS. 15 to 19). It can be seen that the oxidative stress factors are reduced by the administration of UG0712.

Table 20. SOD inhibition rate in muscle of exercise group

SOD (superoxide dismutase) is one of the most important enzymes in the antioxidant enzyme system that makes super-oxide radicals, hydrogen peroxide and oxygen molecules, the first product of aerobic exercise process. That is, SOD plays a role in preventing the formation of peroxynitrate, a strong oxide produced by the reaction of nitric oxide and superoxide (O ^2- ), and regular exercise increases SOD activity. Since it is reported, the antioxidant effect can be confirmed by measuring the SOD oxidation inhibition rate.

As a result, in the UG0712 administration group, the percentage of SOD oxidation inhibition in muscle was increased in the exercise group (FIG. 20). Therefore, it can be seen that the administration of UG0712 can effectively suppress the production of oxide produced by oxidative stress.

Table 21. GPx in muscle of the exercise group

GPx (glutathione peroxidase) is an antioxidant enzyme that has the effect of protecting organs from oxidative damage, and can measure antioxidant activity by analyzing the activity of GPx in muscle.

As a result, the UG0712-administered group showed an increase in muscle GPx in the exercise group compared to the negative control group (FIG. 21). Therefore, it can be seen that administration of UG0712 can effectively protect organs from oxidative damage caused by exercise.

Example 4. ATPase Test

In order to observe the change of muscle fibers by hind limb muscle related to energy use, histochemical staining for myosin ATPase was used as a supplementary indicator of exercise performance.

1) Experiment Method

The left hind limb muscle was cryocutted using a microtome at 20 ° C. at 12 μm. After cryocutting, serial sections were obtained from each block and fixed on a microscope slide while rapidly staining with hemtoxylin-eosin to check the transition of fibrin. Myosin ATPase staining was performed by acid preincubation. At least 200 fibers per muscle were calculated for each animal.

2) results

Table 22.ATPase Test (%) (soleus)

Table 23.ATPase Test (%) (Red gastrocnemius)

Muscles involved in exercise are largely divided into type I and type II fibers by myosin ATPase staining.

Type I fiber is an aerobic energy metabolism that uses glucose and fat as an energy source, which is resistant to fatigue and has a slow contraction speed, which is suitable for long-term endurance exercise.

Type II fiber is anaerobic anaerobic energy metabolism, weak to fatigue and fast contraction speed is suitable for short-term short-distance exercise is commonly called white muscle (white muscle).

Myosin ATPase histochemical staining results to observe changes in type I fibers and type II fibers in the major hind limb muscles involved in exercise. The proportion of oxidative fibers type I fibers was higher than that of the non-motor group. In soleus, type I fiber ratio of exercise test substance UG0712 group was significantly increased (UG0712; P <0.01) compared to non exercise group. The exercise group UG0712 group showed a significant increase (P <0.05.) Of the red gastrocnemius type I fiber ratio compared to the exercise control group (Figs. 22 and 23).

In addition, in the exercise group treated with the test substance for 8 weeks, the type I fiber was slightly increased as compared with the non-exercise group as a whole.

Therefore, when UG0712 was administered, the ratio of oxidative fibers type I fibers to the exercise group was higher than that of the non-exercise group. It is believed to consist of. In addition, this phenomenon was further increased by the test substance UG0712, which is thought to increase the exercise performance on the treadmill.

Example 5 Evaluation of the Effects of Improving Exercise Capacity in the Human Body (VO ₂  max and AT measurements) and safety tests

(1) Test method

Single center, double-blind, random allocation and placebo control methods were used.

Healthy subjects aged 20 years or older who did not exercise regularly within 3 months of the test were selected as subjects. The total number of subjects was 123, but the number of completed subjects was 82. Subjects were randomly assigned to each of the UG0712 high dose group, the UG0712 low dose group, and the control group, and the test was conducted with double blinding.

The UG0712 high dose group consumed a total of 500 mg at 250 mg twice a day, and the UG0712 low dose group consumed a total of 100 mg at 50 mg twice a day. The control group (placebo group) received a total 500 mg dose of 250 mg once a day, once a day CMC (carboxymethylcellulose).

The duration of administration of the test product was 12 weeks, and each subject performed a fixed exercise (3 times a week, aerobic exercise and strength exercise for 60 to 90 minutes). Aerobic exercise was carried out using a treadmill and ergometer with 70-80% VO ₂ max intensity. The number of exercise was measured periodically every two weeks. The sports center designated by the research institute was used three times a week.

VO ₂ max and AT were assessed on the day of ingestion of the test formulation, on the 4th, 8th and 12th weeks, and tested for safety.

(2) VO ₂ max measurement

VO ₂ max was measured to evaluate the effect of improving motor performance.

The results of VO ₂ max (maximum oxygen intake) analysis for the entire subject group showed that the mean of Change3 at the last visit (Visit 5) compared to the baseline was 5.11 ± 4.81 ml / kg / min, The low-dose group was 4.20 ± 5.49ml / kg / min, and the placebo group was 2.34 ± 2.99ml / kg / min. The two UG0712 groups, except the placebo group, showed statistically significant increase by visit (RM ANOVA, high-dose group p). = 0.0002, low dose group 0.0045). The differences between baseline values in visits 3, 4, and 5 were higher in the two UG0712 groups than in the placebo group, and the differences between the groups in the high-dose versus placebo group were statistically significant (RM ANCOVA, p = 0.0292) (Table 24, FIG. 24). 24).

Table 24. VO ₂ max measurements (Unit = ml / kg / min ) (ITT)

Aid group Visit N Mean SD Median Min Max P-value ¹⁾ High capacity Base value 39 28.64 4.87 27.73 20.61 39.72 0.0002 UG0712 Visit 3 39 30.78 5.22 30.96 20.58 42.50 Visit 4 39 31.62 4.95 31.18 20.80 41.13 Visit 5 39 33.74 4.88 34.20 20.80 44.53 Change 1 39 2.15 3.51 1.86 -4.27 9.88 Change 2 39 2.98 4.17 3.02 -7.51 11.21 Change 3 39 5.11 4.81 5.15 -5.94 19.63 Low dose Base value 39 29.09 4.74 28.72 20.38 40.65 0.0045 UG0712 Visit 3 39 30.61 5.12 30.63 20.38 40.65 Visit 4 39 32.03 5.28 31.81 20.38 40.65 Visit 5 39 33.28 6.02 33.00 19.05 45.39 Change 1 39 1.52 2.72 0.00 -3.08 8.52 Change 2 39 2.94 4.23 1.27 -3.08 15.16 Change 3 39 4.20 5.49 2.84 -6.60 18.51 Placebo group Base value 39 30.42 6.73 29.71 20.33 49.89 0.4735 Visit 3 39 31.34 6.32 30.34 21.40 51.50 Visit 4 39 31.63 6.62 30.33 20.00 51.50 Visit 5 39 32.77 6.63 31.27 21.40 51.50 Change 1 39 0.92 3.65 0.14 -8.04 10.08 Change 2 39 1.21 3.12 1.19 -5.12 7.70 Change 3 39 2.34 2.99 1.61 -5.12 8.63 P-value ²⁾ High dose group vs placebo group 0.0292 Low dose group vs placebo group 0.2537

1) Change over time: RM ANOVA

2) Difference between treatment groups: RM ANCOVA (Dunnett's multiple comparison)

Change 1: Visit-based value, Change 2: Visit 4-based value, Change 3: Visit 5-based value

The aerobic capacity of an individual means how much oxygen he or she can use during maximum or exhaustion exercise, which can be seen from VO ₂ max. In other words, VO ₂ max is the functional capacity of each individual, it is an important variable to know the ability of the lung to carry oxygen to the blood, the blood pumping function of the heart and the process of pumped blood to the muscle.

As a result, VO ₂ max, which represents aerobic exercise capacity, ie cardiopulmonary endurance, was significantly increased in the UG0712 high-dose group compared to the placebo group (RM ANCOVA, VO ₂ max p = 0.0292).

(3) AT (anaerobic threshold)

AT (anaerobic threshold) was measured to evaluate the effect of improving motor performance.

Analytical threshold (AT) analysis of the entire subject group (ITT group) shows that Change3 at the last visit compared to baseline was 1.63 ± 4.18ml / kg / min for the high dose group and 0.19 ± 3.59ml / for the low dose group. The kg / min and placebo groups were -0.01 ± 4.74 ml / kg / min. The two UG0712 groups increased with the visit. The difference in baseline 3, 4, 5 compared to baseline was higher in the two UG0712 groups than in the placebo group, among which the high-dose versus placebo group showed a statistically significant difference (RM ANCOVA, p = 0.0378) (Table 25, FIG. 25). 25).

Table 25.AT Measurement Results (Unit = mL / kg / min) (ITT)

Aid group Visit N Mean SD Median Min Max P-value ¹⁾ High capacity Base value 39 19.28 4.23 18.75 9.55 32.00 0.2476 UG0712 Visit 3 39 19.94 3.63 19.48 13.26 28.24 Visit 4 39 20.23 2.85 20.74 15.73 28.59 Visit 5 39 20.91 3.47 20.40 15.76 28.65 Change 1 39 0.66 4.03 0.54 -9.71 6.96 Change 2 39 0.95 3.93 1.21 -11.84 8.31 Change 3 39 1.63 4.18 0.93 -9.75 9.93 Low dose Base value 39 18.83 3.46 19.03 12.87 29.04 0.9956 UG0712 Visit 3 39 18.96 3.13 19.18 12.94 29.04 Visit 4 39 18.96 3.46 19.18 12.94 29.04 Visit 5 39 19.02 3.72 19.18 10.43 29.04 Change 1 39 0.14 1.96 0.00 -4.36 4.88 Change 2 39 0.13 2.89 0.00 -5.64 6.76 Change 3 39 0.19 3.59 0.00 -7.45 7.90 Placebo group Base value 39 20.03 5.11 19.41 12.95 32.91 0.7681 Visit 3 39 19.23 3.98 18.68 12.57 29.52 Visit 4 39 19.32 3.56 18.86 12.58 29.07 Visit 5 39 20.02 4.86 19.08 10.66 36.09 Change 1 39 -0.80 4.69 0.00 -13.11 12.44 Change 2 39 -0.71 4.62 0.00 -13.46 7.83 Change 3 39 -0.01 4.74 0.00 -13.46 9.60 P-value ²⁾ High dose group vs placebo group 0.0378 Low dose group vs placebo group 0.9626

1) Change over time: RM ANOVA

2) Difference between treatment groups: RM ANCOVA (Dunnett's multiple comparison)

Change 1: Visit-based value, Change 2: Visit 4-based value, Change 3: Visit 5-based value

AT refers to a specific point in time when serum lactate levels begin to increase as exercise intensity increases. Higher AT levels mean longer periods of aerobic exercise without anaerobic metabolism. This means you can continue to exercise longer at your pace.

As a result, AT showing aerobic exercise capacity according to the anaerobic threshold increased significantly in the UG0712 high-dose group compared to the placebo group (AT p = 0.0378).

VO ₂ max and AT are independent indicators of aerobic fitness, ie cardiovascular endurance. As a result of the experiment, the UG0712 high-dose group increased the VO ₂ max and AT values to a statistically significant level compared to the control group, through which the aerobic exercise capacity was improved when the normal adult took the UG0712 high-dose (500mg / day). It can be seen that it shows the effect of improving athletic ability and endurance.

(4) safety test

1) Test method

All 117 randomized subjects were included in the analysis because they were able to take UG0712 or placebo and evaluate at least one safety data.

(a) adverse reactions

Adverse events through magnetic / ophthalmic symptoms were assessed from the time of ingestion of the test preparation to 12 weeks after ingestion (visit 5). In addition to the voluntary report of the subject, the patient was confirmed through a questionnaire at each visit, and when the adverse reaction occurred, the symptoms, the occurrence time, duration, the intensity of the adverse reaction, and the causal relationship were recorded in detail in the case record. Other clinically significant abnormal laboratory tests and vital signs were also reported as adverse events.

(b) General findings

Vital signs, ie blood pressure (mmHg), pulse rate (times / minute), were measured after the subject was at least 5 minutes stable. Laboratory tests and physical examination findings (physical tests) were recorded at screening visits (Visit 1) and visits 3, 4 and 5. In the case of clinically significant abnormal findings, the above items were described in detail by treating them as adverse reactions.

2) results

Clinical laboratory tests, vital signs, and physical examinations performed before and after the clinical trial showed no significant changes.There was no statistically significant difference between the treatment group and the placebo group. do.

Figure 1 shows the maximum mileage measurement results of rats after 2 weeks of the exercise group of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 2 shows the maximum mileage measurement results of rats after 8 weeks of the exercise group of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 3 shows the maximum mileage measurement results of rats after 6 weeks of non-exercise group of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 4 shows the maximum mileage measurement results of rats after 9 weeks of the non-exercise group of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 5 shows the results of blood CK (creatine kinase) measurement of rats after the exercise group two weeks exercise of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 6 shows the results of the blood LDH measurement of non-exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 7 shows the results of the blood LDH measurement of rats after 8 weeks of exercise group exercise mixture of ginseng leaf extract and ginseng leaf extract processed product.

Figure 8 shows the results of LDH measurement in the muscle of the exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 9 shows the results of the measurement of lactic acid in the blood of non-exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 10 shows the results of measurement of lactic acid in the blood of the exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 11 shows the results of measurement of blood corticosterone in the non-exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 12 shows the results of blood corticosterone measurement of the exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 13 shows the results of the CS activity in the muscle of the non-exercise group of the mixture of ginseng leaf extract and ginseng leaf extract processed product.

Figure 14 shows the results of the CS activity in the muscle of the exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 15 shows the results of the measurement of blood NO in the non-exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 16 shows the results of the measurement of NO in the muscles of non-exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 17 shows the results of measuring the NO content in the blood collected before the second week of exercise in the exercise group rats administered a mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 18 shows the results of measuring the NO content in the blood collected after the second week of exercise in the exercise group rats administered a mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 19 shows the results of the measurement of the NO in the muscle of the exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 20 shows the results of the measurement of the SOD inhibition (%) in the muscle of the exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 21 shows the results of GPx measurement in the muscle of the exercise group rats of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 22 shows the results of the ATPase test on the soleus muscle of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 23 shows the results of the ATPase test on the red gastrocnemius muscle of the mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 24 shows the results of measuring the change trend of VO ₂ max in the group administered a mixture of ginseng leaf extract and ginseng leaf extract processing.

Figure 25 shows the results of measuring the change in the AT value in the group administered a mixture of ginseng leaf extract and ginseng leaf extract processing.

Claims (18)

An antioxidant composition for enhancing athletic performance and fatigue recovery, comprising a mixture of a leaf extract of the genus Panax and a leaf extract of Panax genus as an active ingredient. The method of claim 1, wherein the leaf extract of the genus Panax plants and mixtures of the processed products thereof include 3-O-glycoside derivatives of Protopanaxanatriol and 3-O-glycoside derivatives of Protopanaxadiol. Composition. The content ratio of 3-O-glycoside derivatives of ProtoPanaxatriol to 3-O-glycoside derivatives of ProtoPanaxadiol in the mixture of leaf extracts of Panax plants and its processed products is 1: 0.5. To 1.5. The content ratio of 3-O-glycosidic derivatives of ProtoPanaxatriol to 3-O-glycoside derivatives of ProtoPanaxadiol in the mixture of leaf extracts of Panax plants and its processed products is 1: 0.7. To 1.5. The composition according to claim 1, wherein the total ginsenoside content in the mixture of the leaf extract of the genus Panax and its processed product is 30 wt% or more. The composition according to claim 1, wherein the total ginsenoside content in the mixture of the leaf extract of the genus Panax and its processed product is 40 wt% or more. The composition of claim 1, wherein the leaf extract of Panax genus plants and the mixture of the processed products thereof contain at least one component selected from the group consisting of ginsenosides Rg3, Rg5 and Rk1 as active ingredients. 8. The composition of claim 7, wherein the ginsenosides Rg3, Rg5 and Rk1 content in the mixture is at least 5 wt%. 8. The composition of claim 7, wherein the ginsenosides Rg3, Rg5 and Rk1 content in the mixture is at least 10 wt%. According to claim 1, Panax plants include Panax ginseng , Panax japonicum , Panax quinquefolium , Panax notoginseng , Panax trifolium , Panax pseudo ginseng (Panax pseudoginseng), Vietnamese ginseng (Panax vietnamensis), which is selected from the group consisting of Panax elegans are tees climb (Panax elegatior), Panax Wan Jia Taunus (Panax wangianus) and Panax non pinra typhimurium Douce (Panax bipinratifidus) Characterized in that the composition. The composition of claim 1, wherein the leaf extract of the genus Panax and the leaf extract processed product of the genus Panax are mixed in a ratio of 1: 0.1 to 5. The composition of claim 1, wherein the leaf extract of the genus Panax and the leaf extract processed product of the genus Panax are mixed at a ratio of 1: 0.1 to 3. The composition of claim 1, wherein the composition is enhanced by enhancing VO ₂ max or Anaerobic threshold, or by increasing mileage, type I muscle or citrate synthase activity. . The composition of claim 1, wherein fatigue recovery is enhanced by reducing the level of one or more fatigue factors selected from the group consisting of creatine kinase, lactic acid dehydratase (LDH), lactic acid and corticosterone. The composition of claim 1, wherein the composition is inhibited by inhibiting nitric oxide (NO), superoxide dismutase (SOD) oxidation, or enhancing glutathione peroxidase (GPx) activity. The mixture of the extract of the leaf extract of the genus Panax and the leaf extract of the genus Panax, (a) the leaves of Panax genus plants are refluxed with an extraction solvent selected from the group consisting of water, C _1-4 alcohols, and mixed solvents thereof, and then lyophilized to obtain leaf extracts of Panax genus plants, (b) adding water and glacial acetic acid to the obtained extract powder, performing a processing reaction with stirring at 60-100 ° C., and drying to obtain a processed product of the leaf extract of the genus Panax plant, (c) a composition of the leaf extract of the genus Panax plant obtained in (a) and the processed product of the leaf extract of the genus panax plant obtained in (b). 17. The composition of claim 16, wherein the extractant is ethanol. The method according to claim 1, wherein in the group consisting of squalene, triticale water extract, cucumber extract, Cordyceps sinensis extract, collagen powder or extract, vitamins, minerals, taurine, creatine, phosphatidylcholine, glutamine, L-arginine and L-carnitine The composition further comprises at least one component selected.

Images